-
Mashup Score: 0PROACTIVE Trial to Use Neoadjuvant Approach in Unresectable Pancreatic Adenocarcinoma - 17 day(s) ago
The pilot trial is planning to enroll 20 patients who are deemed inoperable but do not have metastatic disease.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0SNB-101 Receives Orphan Drug Designation in Pancreatic Cancer - 2 month(s) ago
SNB-101, a novel polymer nanoparticle agent, has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
The FDA has granted orphan drug designation to cambritaxestat for use as a potential therapeutic option in patients with pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0SNB-101 Receives Orphan Drug Designation in Pancreatic Cancer - 2 month(s) ago
SNB-101, a novel polymer nanoparticle agent, has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NALIRIFOX Approval Revitalizes Pancreatic Cancer Management - 2 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NALIRIFOX Approval Revitalizes Pancreatic Cancer Management - 2 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0IMM-1-104 Earns FDA Fast Track Designation in Pancreatic Cancer - 2 month(s) ago
Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Unlocking Insights Into Pancreatic Cancer and Cachexia - 2 month(s) ago
In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NALIRIFOX Approval Revitalizes Pancreatic Cancer Management - 2 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Steven R. Grossman, MD, PhD, from @uscnorris discussed if NAT plus surgery will allow for R0 resection in those with #pancsm. https://t.co/gxYpgdJhax